Insiders who reported open-market trades in the last 12 months at the companies Rahul D. Ballal files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
ORBIMED ADVISORS LLC - $51.68M in ELVN purchases and sales in the last 12 months
Mika K. Derynck - $9.56M in ELVN purchases and sales in the last 12 months
Rahul D. Ballal is a corporate insider, tracked as Director of AGIOS PHARMACEUTICALS, INC. (AGIO). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Rahul D. Ballal last file a Form 4?
The most recent primary Form 4 on record is dated 23 June 2026, one of 5 filings going back to 2024.
Has Rahul D. Ballal been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($1.41M) across all tracked filings.
Rahul D. Ballal is Director of AGIOS PHARMACEUTICALS, INC. (AGIO). 5 SEC Form 4 filings on record going back to 2024, most recently on 23 June 2026. Most recent open-market trade: sold $89K of AGIO on 12 November 2024. Lifetime open-market sales: $1.41M.
Recent transactions
12
The latest 12 SEC Form 4 transactions reported by Rahul D. Ballal.
InsiderAlpha's records for Rahul D. Ballal go back to 2024: 5 primary Form 4 filings, an average of 1.7 per year. 14 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
